Prenumeration
Gentian Diagnostics ASA (”Gentian” or ”the Company”) is a Norwegian in vitro diagnostics (IVD) company specializing in the development of high-quality diagnostic tests for infections, inflammations, kidney failure and heart diseases. With a robust portfolio of established products such as Cystatin C and a strong pipeline of new products such as NT-proBNP, a cardiac biomarker designed to diagnose heart conditions, Gentian is well-positioned to capitalize on the increasing demand for efficient, automated diagnostic solutions. The Company’s strategy focus on sustained revenue growth, driven by expanding market adoption and strategic partnerships. With a clear roadmap for profitability, supported by scalable operations and a growing presence in key markets such as APAC, Analyst Group expects sustained growth and long-term value creation. Gentian is estimated to reach an EBITDA of NOK 68.3m in 2027 and based on an applied EV/EBITDA target multiple of 13.8x, a potential price per share of NOK 71.4 is derived in a Base scenario.
Read the equity research report here
About Analyst Group: One of Sweden's leading analysis houses with a focus on small and medium-sized listed companies.
Read more about Analyst Group
This is a press release from Analyst Group regarding the publication of an independent equity research report on Gentian Diagnostics. Gentian Diagnostics has had no opportunity to influence the parts where the Analyst Group has had opinions about the Company, future valuation or anything else that could conceivably constitute a subjective assessment